FDA Reform Legislation: Hearings Before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, Second Session, on H.R. 3199, 3200, and 3201, May 1 and 2, 1996, Volume 4
United States, United States. Congress. House. Committee on Commerce. Subcommittee on Health and the Environment
U.S. Government Printing Office, 1996 - Drugs - 458 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Pendergast Mary K Deputy Commissioner Senior Advisor to Commis
Other editions - View all
action additive agency AIDS allow American animal application approval approval process Association authority believe benefit bill blood cancer Center Chairman changes claims clinical committee companies concerns Congress consumers continue cost decision determine diseases drugs effective efficacy establish evaluation example existing experience fact FDA's Federal final human important improve independent industry inspections interest issue KESSLER labeling legislation look manufacturers medical devices medicine meet organizations patients performance permit pharmaceutical physicians prescription present problems promote proposed protect public health question reasonable reform regulation regulatory requirements response result risk rules safe safety scientific serious significant specific sponsor standards statement studies submitted testimony testing Thank third party tion treatment trials United